These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1530700)
21. A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA). Kemeny N; Seiter K; Martin D; Urmacher C; Niedzwiecki D; Kurtz RC; Costa P; Murray M Ann Intern Med; 1991 Dec; 115(12):946-51. PubMed ID: 1824554 [TBL] [Abstract][Full Text] [Related]
22. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669 [TBL] [Abstract][Full Text] [Related]
23. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772 [No Abstract] [Full Text] [Related]
25. Chemotherapy of advanced cancer of the colon and rectum. Bruckner HW; Motwani BT Semin Oncol; 1991 Oct; 18(5):443-61. PubMed ID: 1925632 [No Abstract] [Full Text] [Related]
26. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole. Markman M; Chan TC; Cleary S; Howell SB Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730 [TBL] [Abstract][Full Text] [Related]
27. Biochemical modulation: a modality that has come of therapeutic age. Allegra CJ J Clin Oncol; 1991 Oct; 9(10):1723-6. PubMed ID: 1919622 [No Abstract] [Full Text] [Related]
28. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. Ragnhammar P; Blomgren H Med Oncol; 1995 Sep; 12(3):187-201. PubMed ID: 8852401 [No Abstract] [Full Text] [Related]
29. Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation. Stolfi RL; Colofiore JR; Nord LD; Martin DS Anticancer Drugs; 1996 Jan; 7(1):100-4. PubMed ID: 8742105 [TBL] [Abstract][Full Text] [Related]
30. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial. Presant CA; Ardalan B; Multhauf P; Chan C; Staples R; Green L; Browning S; Carr BI; Chang FF; Thayer W Med Pediatr Oncol; 1983; 11(3):162-3. PubMed ID: 6222250 [TBL] [Abstract][Full Text] [Related]
31. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. Harstrick A; Köhne CH; Hiddemann W; Preusser P; Strumberg D; Berns T; Seeber S; Wilke H; Schmoll HJ Ann Oncol; 1997 Sep; 8(9):917-8. PubMed ID: 9358946 [TBL] [Abstract][Full Text] [Related]
32. A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study. Morrell LM; Bach A; Richman SP; Goodman P; Fleming TR; MacDonald JS Cancer; 1991 Jan; 67(2):363-6. PubMed ID: 1985731 [TBL] [Abstract][Full Text] [Related]
33. A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. Windschitl HE; O'Connell MJ; Wieand HS; Krook JE; Rubin J; Moertel CG; Kugler JW; Pfeifle DM; Goldberg RM; Laurie JA Cancer; 1990 Sep; 66(5):853-6. PubMed ID: 2201430 [TBL] [Abstract][Full Text] [Related]
34. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man. Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467 [No Abstract] [Full Text] [Related]
35. Cancer chemotherapy: past is prologue. Martin DS Mt Sinai J Med; 1985 Jun; 52(6):426-34. PubMed ID: 3875021 [No Abstract] [Full Text] [Related]
36. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776 [TBL] [Abstract][Full Text] [Related]
37. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178 [TBL] [Abstract][Full Text] [Related]
38. Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ; Creaven PJ; Petrelli NJ Semin Oncol; 1995 Oct; 22(5):509-24. PubMed ID: 7570061 [No Abstract] [Full Text] [Related]
39. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991 [TBL] [Abstract][Full Text] [Related]
40. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens. O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]